Experimental CAR t therapy takes on solid tumors in first human trial
NCT ID NCT06193902
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe dose and check for any early signs that the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LEU011 (a type of immunotherapy using the patient's own immune cells, called CAR T cells, engineered to target NKG2D ligands on tumor cells)
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early, first-in-human trial with only 17 participants, so safety and effectiveness are not yet known. CAR T cell therapies can cause serious side effects like cytokine release syndrome or nerve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guy's and St Thomas' NHS Foundation Trust
RECRUITINGLondon, SE1 9RT, United Kingdom
Contact
Contact Phone: •••-•••-••••
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
Contact
Contact